Richard Rosenberg, MD
Neurology · Morristown, NJNPI 1598766636
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 1,000 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.
Across 1,000 payments — averaging $14.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$1K
- Biogen$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Bristol Myers Squibb$522
- CSL Behring$522
- plus $8K from 54 others
Across 2 payments — averaging $3856.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$8K
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$300%
- Food & beverage$14,22098%
- Education$1431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$150
- Hizentra$125
- GORE CARDIOFORM Septal Occluder$111
How this compares
$14,543 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 28 | $224,154 |
| Plegridy PenPeginterferon Beta-1a | 12 | $94,627 |
| CopaxoneGlatiramer Acetate | 13 | $74,599 |
| Glatiramer Acetate | 21 | $38,611 |
| Nurtec OdtRimegepant Sulfate | 18 | $35,979 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $28,460 |
| Emgality PenGalcanezumab-Gnlm | 24 | $16,909 |
| NamzaricMemantine Hcl/Donepezil Hcl | 23 | $14,294 |
| Dalfampridine ErDalfampridine | 29 | $10,461 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,329 |
| EliquisApixaban | 12 | $7,330 |
| Memantine Hcl | 169 | $7,094 |
| DepakoteDivalproex Sodium | 24 | $7,071 |
| Dimethyl Fumarate | 30 | $6,456 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 135 | $6,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $1,045 | $224,15428 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $1,025 | $74,59913 claims |
| PfizerNurtec Odt, Eliquis, Dilantin | $426 | $48,04747 claims |
| AbbVieNamzaric | $2,204 | $14,29423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.
Other neurology in Morristown
- Mark DiamondMorristown$93K
- Stuart FoxMorristown$49K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.